Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 5/2009

Open Access 01-10-2009 | Review Article

What can be learned from the history of recurrence in migraine? A comment

Author: Peer Tfelt-Hansen

Published in: The Journal of Headache and Pain | Issue 5/2009

Login to get access

Abstract

Recurrence was first recognised as a clinical problem in 1989 with the advent of sumatriptan. The history of recurrence in early sumatriptan randomised clinical trials is described. Recurrence has been ascribed to patient-dependent factors but experience with ergot alkaloids suggested that recurrence can also be treatment-dependent. Possible mechanisms for recurrence are discussed.
Literature
1.
Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, Ferrari MD (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60:452–460 8873693, 10.1016/S0009-9236(96)90202-7, 1:CAS:528:DyaK28XmvFWku7s%3DCrossRefPubMed
2.
Pilgrim AJ (1991) Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur J Neurol 31:295–299 10.1159/000116757, 1:STN:280:DyaK3MzlslSgtw%3D%3DCrossRef
3.
Lipton RB, Hamelsky SW, Dayno JM (2002) What do patients with migraine want from acute migraine treatment? Headache 42(suppl 1):S3–S9 10.1046/j.1526-4610.2002.0420s1003.xCrossRef
4.
Lantéri-Minet M (2005) What do patients want from their acute migraine therapy? Eur Neurol 53(suppl 1):3–9 15920331, 10.1159/000085036CrossRefPubMed
5.
Gallagher R (2004) What do patients want from acute migraine treatment? Cephalalgia 24(suppl 2):8–15 15595989, 10.1111/j.1468-2982.2004.00893.xCrossRefPubMed
6.
Tfelt-Hansen P, Brand J, Dano P, Doenicke A, Findley LJ, Iversen HK et al (1989) Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia 9(suppl 9):73–77 2544287PubMed
7.
International Headache Society Committee on Clinical Trials in Migraine (1991). Guidelines for controlled trials of drugs in migraine, 1st edn. Cephalalgia 11:1–12
8.
International Headache Society Clinical Trial Subcommittee (2000). Guidelines for controlled trials of drugs in migraine, 2nd edn. Cephalalgia 20:765–786
9.
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675 11728541, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3DCrossRefPubMed
10.
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831–2835 1851894, 10.1001/jama.265.21.2831, 1:STN:280:DyaK3M3jsl2ntw%3D%3DCrossRefPubMed
11.
The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatriptan—an oral dose-defining study. Eur Neurol 31:300–305 10.1159/000116632CrossRef
12.
Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR (1992) Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 52:635–642 1333934, 1:STN:280:DyaK3s%2Fpt1Ghtg%3D%3DCrossRefPubMed
13.
The Oral Sumatriptan International Multiple-Dose Study Group (1991) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 31:306–313 10.1159/000116758CrossRef
14.
The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Eng J Med 325:316–321 10.1056/NEJM199108013250504CrossRef
15.
Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259–1287 11152011, 10.2165/00003495-200060060-00003, 1:CAS:528:DC%2BD3MXktFarsA%3D%3DCrossRefPubMed
16.
Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 469–503
17.
The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 32:177–184 10.1159/000116818CrossRef
18.
Multinational Oral Sumatriptan and Cafergot Coparative Study Group (1991) A randomized, double-blind comparison of sumatriptan in the acute treatment of migraine. Eur Neurol 31:314–322 10.1159/000116759CrossRef
19.
Saxena PR, Tfelt-Hansen P (1993) Sumatriptan. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches. Ravens Press, New York, pp 329–341
20.
Saxena PR, Tfelt-Hansen P (2000) Triptans, 5-HT1B/1D receptor agonists, in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 411–438
21.
Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658 12383060, 10.1046/j.1468-2982.2002.00404.x, 1:STN:280:DC%2BD38njtlehtw%3D%3DCrossRefPubMed
22.
Rapoport A, Visser WH, Cutler NR, Alderton CJ, Paulsgrove LA, Davis RL et al (1995) Oral sumatriptan in preventing headache recurrence after treatment of migraine arracks with subcutaneous sumatriptan. Neurology 45:1505–1509 7644049, 1:CAS:528:DyaK2MXns1Sis70%3DCrossRefPubMed
23.
Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Andersson BA (1994) Oral sumatriptan: effect of a second dose, and treatment of headache recurrence. Cephalalgia 14:330–338 7828190, 10.1046/j.1468-2982.1994.1405330.x, 1:STN:280:DyaK2M7ivFWjsw%3D%3DCrossRefPubMed
24.
Scott RJ, Aitchison WRC, Barker PR, McLaren GI (1996) Oral treatment in the acute treatment of migraine and migraine and migraine recurrence in general practice. Q J Med 89:613–622 1:STN:280:DyaK2s%2FovFGktg%3D%3DCrossRef
25.
Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ et al (2007) Sumatriptan-naproxen for acute treatment of migraine. A randomized trial. JAMA 297:1443–1454 17405970, 10.1001/jama.297.13.1443, 1:CAS:528:DC%2BD2sXjvFCjt74%3DCrossRefPubMed
26.
Visser WH, Jaspers NM, de Vriend RH, Ferrari MD (1996) Risk factors for headache recurrence after sumatriptan. A study in 366 migraine patients. Cephalalgia 16:264–269 8792039, 10.1046/j.1468-2982.1996.1604264.x, 1:STN:280:DyaK28zosVWnsA%3D%3DCrossRefPubMed
27.
Dodick DW, Lipton RB, Goadsby PJ, Tfelt-Hansen P, Ferrari MD, Diener H-C, Almas M, Albert KS, Parsons B (2008) Predictor of migraine headache recurrence a pooled analysis from the eletriptan data base. Headache 48:184–193 18234045PubMed
28.
Géraud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43:376–388 12656709, 10.1046/j.1526-4610.2003.03073.xCrossRefPubMed
29.
Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L (2005) Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 19:125–136 15697326, 10.2165/00023210-200519020-00003, 1:CAS:528:DC%2BD2MXislCqs7s%3DCrossRefPubMed
30.
Spierings EL, Rapoport AM, Dodick DW, Charlesworth B (2004) Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 18:1133–1141 15581383, 10.2165/00023210-200418150-00007, 1:CAS:528:DC%2BD2MXmvVSlsA%3D%3DCrossRefPubMed
31.
Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH on behalf of the Rizatriptan 030 study Group (1998) Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 38:748–755 11284463, 10.1046/j.1526-4610.1998.3810748.x, 1:STN:280:DC%2BD3M3js1eiug%3D%3DCrossRefPubMed
32.
Tfelt-Hansen P (2008) Frovatriptan and data publication. Headache 48:1382–1383 19006553, 10.1111/j.1526-4610.2008.01064.xCrossRefPubMed
33.
Headache Classification Committee of the International Headache Society (2004) Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain, 2nd edn. Cephalalgia 24(suppl 1):1–164
34.
Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Schayck RV et al (1995) Brainstem activation in spontaneous human migraine attacks. Nat Med 1:658–660 7585147, 10.1038/nm0795-658, 1:CAS:528:DyaK2MXms1Kgsbs%3DCrossRefPubMed
35.
Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowick RS et al (2005) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128:932–939 15705611, 10.1093/brain/awh416, 1:STN:280:DC%2BD2M7lsV2jug%3D%3DCrossRefPubMed
36.
Diener HC, May A (1996) New aspects of migraine pathophysiology: lessons learned from positron emission tomography. Curr Opin Neurol 9:199–201 8839610, 10.1097/00019052-199606000-00007, 1:STN:280:DyaK28vjs1Oqtg%3D%3DCrossRefPubMed
37.
Kelman L (2006) The postdrome of the acute migraine attack. Cephalalgia 26:214–220 16426278, 10.1111/j.1468-2982.2005.01026.x, 1:STN:280:DC%2BD28%2FjvFSqtg%3D%3DCrossRefPubMed
38.
Goadsby PJ, Dodick D, Almas M, Diener H-C, Tfelt-Hansen P, Lipton RB, Parsson B (2007) Treatment emergent CNS symptoms following triptan therapy are part of the migraine attack. Cephalalgia 27:254–262 17381558, 10.1111/j.1468-2982.2007.01278.x, 1:STN:280:DC%2BD2s7otFKgtg%3D%3DCrossRefPubMed
39.
Tfelt-Hansen P, Paalzow L (1985) Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 37:29–35 3917386, 1:STN:280:DyaL2M%2FnsFeksg%3D%3DCrossRefPubMed
40.
Østergaard JR, Mikkelsen E, Voldby B (1981) Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery. Cephalalgia 1:223–228 7347625, 10.1046/j.1468-2982.1981.0104223.xCrossRefPubMed
41.
Tfelt-Hansen P, Østergaard JR, Göthgen I, Jacobsen E, Rasmussen JP, Husum B (1982) Nitroglycerin for ergotism-experimental studies in vitro and in migraine patients and treatment of an overt case. Eur J Clin Pharmacol 22:105–109 6807695, 10.1007/BF00542453, 1:CAS:528:DyaL38XktFKrtb8%3DCrossRefPubMed
42.
MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998) Coronary side effect potential of current and prospective antimigraine drugs. Circulation 98:25–30 9665056, 1:STN:280:DyaK1czisl2qsQ%3D%3DCrossRefPubMed
43.
Tfelt-Hansen P, Nilsson E, Edvinsson L (2007) Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat. J Headache Pain 8:83–89 17497262, 10.1007/s10194-007-0368-9, 1:CAS:528:DC%2BD2sXlt1CgtrY%3DPubMedCentralCrossRefPubMed
44.
Müller-Schweinitzer E (1984) What is known about the action of dihydroergotamine on the vasculature in man? Int J Clin Pharmacol Ther Toxicol 22:677–682 6396240PubMed
45.
Müller-Schweinitzer E (1980) In vitro study on the duration of action of dihydroergotamine. Int J Clin Pharmacol Ther Toxicol 18:88–91 7372380PubMed
Metadata
Title
What can be learned from the history of recurrence in migraine? A comment
Author
Peer Tfelt-Hansen
Publication date
01-10-2009
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 5/2009
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-009-0144-0

Other articles of this Issue 5/2009

The Journal of Headache and Pain 5/2009 Go to the issue

Original

Psychometric properties of the Danish versions of Headache-Specific Locus of Control Scale and Headache Management Self-Efficacy Scale

Original

Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism

Editorial

While climbing the hill, you think it’s possible

Original

Trigger factors in childhood migraine: a clinic-based study from Eastern India

Review Article

Migraine pain: reflections against vasodilatation

Brief Report

SUNCT and optic nerve hypoplasia